Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

Start Date01 Aug 2026

Sponsor / Collaborator-

NCT06693752

/ RecruitingPhase 2

Pilot Study of Improved Diagnosis and Monitoring of Hydrocephalus in Neonates and Infants Using Contrast-Enhanced Ultrasound

Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to assess the safety and feasibility of performing brain contrast-enhanced ultrasound (CEUS) in neonates and infants with diagnosed and/or suspected hydrocephalus.

Start Date01 Sep 2025

Sponsor / Collaborator

The Children's Hospital of Philadelphia

CTRI/2025/04/085276

/ Not yet recruitingNot ApplicableIIT

Comparative Evaluation of the Antimicrobial Efficacy of Fluoride Varnish with Xylitol and Fluoride Varnish with CPP-ACP in children with Early Childhood Caries : A Randomized Clinical Study. - NIL

Start Date15 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Sulfur Hexafluoride

100 Translational Medicine associated with Sulfur Hexafluoride

100 Patents (Medical) associated with Sulfur Hexafluoride

15,347

Literatures (Medical) associated with Sulfur Hexafluoride

01 Nov 2025·INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER

Turbulent self-quenching mechanism of high-temperature-gradient arc plasma in a converging–diverging cylinder: a numerical study

Author: Tanaka, Yasunori ; Inada, Yuki ; Shigeta, Masaya

Thermofluid dynamic behaviors of SF₆ and air flows including arc plasma and non-ionized gas in a converging-diverging cylinder were studied numerically.The arc plasma in SF₆ gas was constricted with high temperatures exceeding 20 000 K.It formed a slightly compressible and subsonic flow, whereas the ambient non-ionized gas had temperatures below 1000 K and a compressible flow with island-like supersonic flow zones.The arc plasma in air gas had temperatures lower than 12 000 K and a blurred fringe with a low gradient.The entire fluid region including the plasma formed an incompressible and subsonic flow.The different temperature distributions were attributed to differences of their thermal diffusivities and Reynolds numbersFor the SF₆ flow system, SF₆ mols. dissociated in the arc plasma to seven atoms.They were ionized to their ions and electrons, causing considerably greater volume expansion and generating both forward and backward flows locally.Impingements of those flows occurred locally.The generated vortices conveyed the thermal energy outward.Great degrees of turbulent mixing of the thermal energy occurred with the mass d. fluctuation, which produced outward heat flux much stronger than that produced by either convection or conduction.The arc plasma was quenched effectively.

01 Oct 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Dichloromethane-knitting synthesis of fluorinated porous organic polymers for superior sulfur hexafluoride adsorption and separation

Author: Wang, Enhui ; Peng, Yuyue ; Li, Lina ; Li, Zhiyi ; Lei, Hongliang ; Wang, Youzhi ; Su, Hongmin ; Meng, Timur ; Chaleawlert-umpon, Saowaluk

Sulfur hexafluoride (SF₆), a crucial gas in the power and semiconductor industries, presents significant challenges for recovery and separationThis work reports the synthesis of a series of porous organic polymers (POPs) with high porosity and physicochem. stability via a Lewis acid-catalyzed slow-knitting method.Different fluorinated organic monomers were employed, using dibromomethane (DBrM) as both solvent and electrophilic cross-linker.The resulting DBrM-knitted POPs exhibited BET surface areas up to 1,408.37 m²/g, surpassing those of chloroform-knitted POPs by 53.51-160.26 %.These materials demonstrated superior SF₆ adsorption capacity, tunable via the position of fluorine groups.The optimal material achieved an SF₆ adsorption capacity of 91 mL/g at 273 K and an SF₆/N₂ separation selectivity of 195.70.An optimal pore size of 0.73 nm was identified for SF₆ adsorption and separationThese findings contribute significantly to the development of advanced porous materials for efficient SF₆ recovery.

01 Oct 2025·SEPARATION AND PURIFICATION TECHNOLOGY

ZIF-8 membranes for highly efficient SF6 recovery

Author: Dai, Yurun ; Wang, Haihui ; Zhao, Yali ; Cao, Changdie ; Wei, Yanying ; Xia, Qibin

Sulfur hexafluoride (SF₆) is a commonly utilized insulation gas in elec. equipment because to its superior insulating capabilities and arc extinguishing characteristics, which holds high recycling value and necessity from the economic and environmental perspective.However, traditional method of recovering SF₆ based on cryogenic distillation is energy consuming, alternative separation technic is urgently required.Herein, a variety of ZIF-8 membranes fabricated via fast current-driven synthesis are proposed for N₂/SF₆ separationFor a typical insulation gas in gas insulated switchgear comprising 70 % N₂ and 30 % SF₆, the ZIF-8 membrane presents a N₂/SF₆ selectivity up to 809 and a high N₂ permeance of 557 GPU with outstanding pressure resistance, which indicates that the ZIF-8 membrane separation would be an excellent new route for highly efficient SF₆ recovery.

News (Medical) associated with Sulfur Hexafluoride

06 Aug 2025

·www.prnewswire.com

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency

New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 5, 2025 /PRNewswire/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China's National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). This regulatory approval represents an important milestone in the management of infertility because, unlike laparoscopic assessment of tubal patency with use of a dye, HyCoSy is a non-invasive procedure, and, unlike traditional X-ray hysterosalpingography, HyCosy does not expose to radiation the genital tract of women in their reproductive years (4-6). "The NMPA approval of SonoVue® use with HyCoSy marks an important step in expanding access to non-invasive, radiation-free detection of tubal issues and uterine problems that often cause infertility in women," said Alberto Spinazzi, Chief Medical and Regulatory Officer, Bracco Group. "We strive to provide healthcare professionals in China with solutions that advance standards of care, reflecting our commitment to advancing diagnostic precision and improving the patient experience through contrast-enhanced ultrasound." "We are proud to support China's healthcare priorities through solutions like SonoVue® that may help address important diagnostic needs," said Valtero Canepa, Head of APAC, Bracco Imaging. "This new indication advances Bracco's role in delivering meaningful innovation in support of the Healthy China 2030 initiative, which prioritizes earlier detection, clinical precision, and broader access to reproductive health services." The high diagnostic performance of HyCoSy with SonoVue® has been confirmed by a recent systematic review and meta-analysis of 24 clinical studies (total of 1358 women with infertility and 2661 fallopian tubes). Using laparoscopic chromotubation dye test as the standard of truth for the assessment of fallopian tube patency, the pooled estimates of sensitivity, specificity, and accuracy of HyCoSy with SonoVue® were 93%, 90%, and 96%, respectively (1). Backed by over 20 years of clinical use, SonoVue® is the ultrasound contrast agent with the largest number of approved indications in the largest number of countries worldwide. The newly approved HyCoSy indication reinforces Bracco Imaging's commitment to expanding non-invasive, high-quality diagnostic tools aligned with evolving clinical standards and national health objectives in China and beyond. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med 2023; 42:7-15 Wang T, Dong T, Nie F. Clinical applications, advances, and future directions in hysterosalpingography. Front Med 2025; 12:1537506 Reproductive Health Branch of Chinese Preventive Medicine Association. Chinese Expert Consensus on Holistic Management of Tubal Factor Infertility (2023 edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics 2023; 39:318-324 Roy KK, Gajapathy SR, Rai R, Zangmo R, Das A, Singhal S. Assessment of Tubal Patency with Selective Chromopertubation at Office Hysteroscopy versus Modified Minilaparoscopy in Infertile Women. Gynecol Minim Invasive Ther 2021; 10:159-165 Perisinakis K, Damilakis J, Grammatikakis J, Theocharopoulos N, Gourtsoyiannis N. Radiogenic risks from hysterosalpingography. Eur Radiol 2003; 13:1522-1528 Sulieman A, Theodorou K, Vlychou M, Topaltzikis T, Roundas C, Fezoulidis I, Kappas C. Radiation dose optimisation and risk estimation to patients and staff during hysterosalpingography. Radiat Prot Dosimetry 2008;128:217-226 For additional information about Bracco's products, and for full prescribing information, please visit . About Bracco Imaging Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at . Media Contacts: Bracco Press Contact: Carolina Bargoni Bracco Imaging, Communications Director [email protected] +39 347 5397738 SOURCE Bracco Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiation TherapyDrug ApprovalDiagnostic Reagents

14 May 2025

·www.businesswire.com

“Clinically compelling” study shows contrast-enhanced ultrasound (CEUS) is safe and saves lives

BOSTON--(BUSINESS WIRE)--A comprehensive new study based on nationwide claims data from more than 11 million patients shows that diagnostic contrast-enhanced ultrasound (CEUS) exams are safe and can lower a patient’s risk of death. The study, posted online today by the Journal of the American Heart Association, found that serious adverse events associated with ultrasound enhancing agents (UEAs) are “uncommon,” occurring in only 1:10,000 cases. This is “an exceptionally strong safety profile,” according to the study’s lead author, Dr. Jordan Strom, Associate Professor of Medicine at Harvard Medical School, Director of the Echocardiography Laboratory at Beth Israel Deaconess Medical Center, and an officer of the International Contrast Ultrasound Society (ICUS). The large, multicenter, nationwide dataset is broadly representative of US healthcare activity, according to the report. The results mirror those published a decade ago and “reassuringly suggest the continued safety of UEAs in practice,” the authors stated. “This clinically compelling study shows that CEUS is very safe, even for our sickest patients, and saves lives,” said Dr. Steven Feinstein, a cardiologist and Co-President of ICUS. CEUS is a reliable and cost-effective diagnostic tool used worldwide to diagnose heart and vascular disease, identify and characterize tumors, monitor chronic gastro-intestinal diseases, evaluate other serious medical conditions and monitor therapy, Dr. Feinstein said. He noted that, unlike contrast agents used for MR or CT, the enhancing agents used in ultrasound exams do not contain dye, create no known risk of kidney damage or brain deposits, and do not expose patients or hospital staff to ionizing radiation. In addition, CEUS exams are often easier on patients, and they provide highly accurate clinical information in real time so that appropriate therapy can be initiated without delay. Dr. Strom said that UEAs are underutilized in North America despite their well-established clinical and economic benefits, and he called upon more medical centers to offer CEUS to their patients. “UEAs can help us get the right diagnosis upfront, reducing unnecessary and costly downstream testing – and that is not only great for patients, it also helps improve health care cost containment and efficiencies, providing a unique win-win opportunity to save money while actually improving clinical care and outcomes,” Dr. Strom added. CEUS is also safe and useful for a wide range of radiology applications, said Dr. Stephanie Wilson, a radiologist at the University of Calgary and Co-President of ICUS. “We use CEUS every day because it safely and consistently provides high resolution images comparable to – and sometimes better than – CT or MR,” Dr. Wilson said. “Many of our patients cannot tolerate CT or MR, especially if they have kidney disease, so for them CEUS may be the only option for advanced imaging,” she added. Key findings of the newly-published study, which covered a four-year period between 2018 and 2022, include: Serious adverse events associated with UEAs were uncommon (occurring in only 1:10,000 administrations). This relatively low risk was similar across brands of UEAs and years of study. This risk also was consistent with findings of older studies. Patients who received UEAs are often sicker than those who don’t receive them. Still, after accounting for differences among individuals, patients who received UEAs had lower risk of death within 2 days of receiving UEAs during an echocardiogram when compared to patients who did not receive UEAs during an echocardiogram. The authors examined rates of anaphylaxis, myocardial infarction, ventricular tachycardia, cardiac arrest or death within 2 days of echocardiograms administered with and without UEAs. The study concluded that the small rate of serious adverse events should be interpreted in the context of higher risks posed by other contrast media and thus should not preclude use. The authors also cautioned that appropriate processes should be in place to mitigate risk and respond urgently to potential anaphylactoid reactions. A smaller study recently suggested that COVID-19 vaccinations may be linked to higher risk of serious adverse events with a single UEA, but the new nationwide analysis found no such link -- regardless of the agent or year of study evaluated, Dr. Strom said. “Our findings should alleviate any residual safety concerns and make a strong case for broader use of UEAs in order to improve patient care and outcomes and save lives,” Dr. Strom said. Three UEAs are currently approved by the US Food and Drug Administration for use in the United States: Definity (Lantheus); Lumason (Bracco Imaging) and Optison (GE Healthcare). ABOUT ICUS: The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources. To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

Clinical Result

27 Feb 2023

·www.sciencedaily.com

New superacid converts harmful compounds into sustainable chemicals

Researchers have succeeded in producing very special catalysts, known as 'Lewis superacids', which can be used to break strong chemical bonds and speed up reactions. The production of these substances has, until now, proven extremely difficult. The chemists' discovery enables non-biodegradable fluorinated hydrocarbons, similar to Teflon, and possibly even climate-damaging greenhouse gases, such as sulphur hexafluoride, to be converted back into sustainable chemicals. Researchers at Paderborn University have succeeded in producing very special catalysts, known as "Lewis superacids," which can be used to break strong chemical bonds and speed up reactions. The production of these substances has, until now, proven extremely difficult. The chemists' discovery enables non-biodegradable fluorinated hydrocarbons, similar to Teflon, and possibly even climate-damaging greenhouse gases, such as sulphur hexafluoride, to be converted back into sustainable chemicals. The researchers have now published their results in the journal Angewandte Chemie (Applied Chemistry). "Lewis acids" are compounds that add electron pairs. Because of this ability, they are often used to speed up chemical reactions. Lewis superacids are stronger than antimony pentafluoride -- the strongest Lewis acid -- and can break even the toughest bonds. Professor Jan Paradies from the Department of Chemistry at Paderborn University explains: "For strong bonds, you need highly reactive reagents, i.e. substances that are extremely reactive." The new catalyst can split, for example, carbon-fluorine or sulphur-fluorine bonds, which are particularly robust. "Intrinsically, these Lewis superacids are incredibly reactive, which makes them difficult to produce and use. Using a trick, we managed to produce such molecules and use them in catalytic reactions. This makes it possible to, for example, activate and further convert virtually inert, i.e. less reactive, carbon-fluorine or sulphur-fluorine bonds," says Paradies. The researchers in the Department of Chemistry have joined forces in the Center for Sustainable Systems Design (CSSD), which bundles interdisciplinary basic research in the field of sustainability at Paderborn University. The complementary scientific interests of the groups involved form the nucleus for new approaches in the development of sustainable systems. The centre wants to leverage this capacity to contribute to the sustainable use of resources. This and related topics are also covered in Paderborn within the framework of its "Sustainable Chemistry" master's programme.

100 Deals associated with Sulfur Hexafluoride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sulfur Hexafluoride	V08DA05	DB11104

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Diseases	China	Bracco International BV	23 May 2003
Liver Diseases	China	Bracco International BV	23 May 2003
Vesico-Ureteral Reflux	China	Bracco International BV	23 May 2003
Cardiovascular Diseases	European Union	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	Iceland	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	Liechtenstein	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	Norway	Bracco International BV	26 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoxia-Ischemia, Brain	Phase 3	United States	Bracco Diagnostics, Inc.	01 Dec 2020
Enterocolitis, Necrotizing	Phase 3	United States	Bracco Diagnostics, Inc.	04 Nov 2020
Heart Defects, Congenital	Phase 3	United States	Bracco Diagnostics, Inc.	01 Oct 2015
Heart Diseases	Phase 3	United States	Bracco Diagnostics, Inc.	01 Oct 2015
Coronary Artery Disease	Phase 3	United States	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Phase 3	Canada	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Phase 3	Germany	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Phase 3	Italy	Bracco Diagnostics, Inc.	24 Sep 2015
Liver Cancer	Phase 3	United States	Bracco Diagnostics, Inc.	01 Sep 2009
Visible Lesion	Phase 3	United States	Bracco Diagnostics, Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03821376 (CTgov)	Phase 4	Renal Cell Carcinoma \| Kidney Neoplasms	12	Lumason	dkumejhzut = evophorawt ygiedqerqx (mcnjkjbwwz, ikbpmtdseb - ahitwkkhpy) View more	-	10 Oct 2024
NCT04569799 (TACE, CTgov)	Phase 4	Hepatocellular Carcinoma	26	Lumason	phlwuwldqw = bnunvddzup veuukmunvz (tdvbvonqdd, idvasaqvjn - xliebwlnqd) View more	-	02 Nov 2023
NCT03687502 (CTgov)	Phase 2	Appendicitis	37	Sulfur hexafluoride lipid-type A microspheres	cmsgprtzrf = umjskfxchh sxohpwbqvq (lvlmokuwyl, xtccftnujc - vqetdopmfo) View more	-	01 Dec 2022
NCT03235180 (CTgov)	Phase 4	Crohn Disease	9	Magnetic Resonance Enterography (MRE)+Sulfur Hexafluoride	rdfoxfqtcd(bupquwurus) = wkyeiycwuk royaqukllu (xdxyscmqiv, 4.07) View more	-	10 Nov 2021
NCT03040323 (CTgov)	Phase 4	-	83	Lumason 60.7Mg Powder for Injection (Biopsy With Lumason)	fuhzkgpaub(sflhkpcmux) = xkrdykwuie snkxqubecp (kxgikkacyl, kwdksjdlml - zijldddqoo) View more	-	24 Jul 2019
NCT03040323 (CTgov)	Phase 4	-	83	Placebos (Biopsy With Placebos)	fuhzkgpaub(sflhkpcmux) = bakblgcuie snkxqubecp (kxgikkacyl, ugmmdekilb - vxwehzaeto) View more	-	24 Jul 2019
NCT02786810 (CTgov)	Phase 2	Kidney Diseases \| Urinary Tract Infections \| Vesico-Ureteral Reflux ... View more	10	Sulfur hexafluoride type-a lipid microspheres	qalozazlks = rtsemulwpw yexmgkmspb (qbzuzkgiva, sinhfjudhx - cigwbfhnqc) View more	-	04 Apr 2018
EAN2017	Not Applicable	Acute Ischemic Stroke	-	Alteplase	zlybhkqoct(dlnmfbltai) = xgcfseedvb gytcsifnfv (drbxypqutx ) View more	-	13 Jul 2017
EAN2017	Not Applicable	Acute Ischemic Stroke	-	Tenecteplase	zlybhkqoct(dlnmfbltai) = mfsyuaxcui gytcsifnfv (drbxypqutx ) View more	-	13 Jul 2017
NCT01306292 (CTgov)	Phase 2	Hypertension, Pulmonary	36	Placebo (Hypertension Placebo)	ijeoydzgqh(xehhyuowcr) = dofhzwsewv lhwhxcvkbc (alcgvwpqfe, 17.581) View more	-	08 Feb 2016
NCT01306292 (CTgov)	Phase 2	Hypertension, Pulmonary	36	SonoVue (Hypertension SonoVue)	ijeoydzgqh(xehhyuowcr) = mlgkqvdjbj lhwhxcvkbc (alcgvwpqfe, 17.581) View more	-	08 Feb 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sulfur Hexafluoride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation